Preserving the Liver for Second-Line Treatment of Hepatocellular Carcinoma

被引：0
|
作者：
Lencioni, Riccardo [1 ,2 ]
机构：
[1] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Intervent Radiol,Intervent Radiol, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Intervent Radiol,Clin & Translat Res, Miami, FL 33136 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 8
页数：3
相关论文
共 50 条
  • [31] Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
    Shao, Y. -Y.
    Chen, B. -B.
    Ou, D. -L.
    Lin, Z. -Z.
    Hsu, C. -H.
    Wang, M. -J.
    Cheng, A. -L.
    Hsu, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (08) : 722 - 730
  • [32] Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study.
    de Rosa, F.
    Agostini, V.
    Di Girolamo, S.
    Andreone, P.
    Trevisani, F.
    Bolondi, L.
    Pinna, A. D.
    Serra, C.
    Golfieri, R.
    Biasco, G.
    Brandi, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
    Villanueva, Augusto
    Llovet, Josep M.
    CLINICAL CANCER RESEARCH, 2012, 18 (07) : 1824 - 1826
  • [34] Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma
    Messner, Martina
    Schmitt, Sabine
    Ardelt, Maximilian A.
    Froehlich, Thomas
    Mueller, Martin
    Pein, Helmut
    Huber-Cantonati, Petra
    Ortler, Carina
    Koenig, Lars M.
    Zobel, Lena
    Koeberle, Andreas
    Arnold, Georg J.
    Rothenfusser, Simon
    Kiemer, Alexandra K.
    Gerbes, Alexander L.
    Zischka, Hans
    Vollmar, Angelika M.
    Pachmayr, Johanna
    FASEB JOURNAL, 2020, 34 (09): : 11860 - 11882
  • [35] Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers
    Rimassa, Lorenza
    Santoro, Armando
    Daniele, Bruno
    Germano, Domenico
    Gasbarrini, Antonio
    Salvagni, Stefania
    Masi, Gianluca
    Abbadessa, Giovanni
    Lamar, Maria
    Goldberg, Terri
    Porta, Camillo
    TUMORI JOURNAL, 2015, 101 (02): : 139 - 143
  • [36] Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
    Trojan, Joerg
    Waidmann, Oliver
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2016, 3 : 31 - 36
  • [37] Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
    Mir, Olivier
    Coriat, Romain
    Boudou-Rouquette, Pascaline
    Ropert, Stanislas
    Durand, Jean-Philippe
    Cessot, Anatole
    Mallet, Vincent
    Sogni, Philippe
    Chaussade, Stanislas
    Pol, Stanislas
    Goldwasser, Francois
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2793 - 2799
  • [38] Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
    Kim, Jung Han
    Kim, Bum Jun
    Jang, Hyun Joo
    Lee, Jin
    ONCOTARGET, 2017, 8 (60) : 102321 - 102327
  • [39] Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Ooka, Yoshihiko
    Suzuki, Eiichiro
    Maeda, Takahiro
    Yokoyama, Masayuki
    Wakamatsu, Toru
    Inoue, Masanori
    Saito, Tomoko
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Nakamoto, Shingo
    Yasui, Shin
    Tawada, Akinobu
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Yokosuka, Osamu
    Kato, Naoya
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 332 - 339
  • [40] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA
    Xiao, D.
    Zhu, S.
    Sun, W.
    Xuan, J.
    VALUE IN HEALTH, 2019, 22 : S187 - S188
12345